On March 12, 2025, BiBo Pharma was honored with the “Emerging CDMO of the Year” award at the Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony hosted by IMAPAC.
Asia-Pacific Biopharma Excellence Awards: A Benchmark for Industry Innovation
The Asia-Pacific Biopharma Excellence Awards (ABEA) seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality. Featuring top bioprocessing and biomanufacturing leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Asia-pacific bioprocessing excellence awards applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.
BiBo Pharma: Setting Sail from Boston, Leading the New Wave of Biopharmaceuticals
Founded in 2014 and headquartered in Boston, BiBo Pharma has achieved commercial-scale production of biologics through its independently designed, ultra-large scale mammalian cell stainless steel bioreactors. Over the past decade, the company’s strategic focus has aligned closely with the growing demand for commercial-scale biomanufacturing, demonstrating its exceptional capabilities in technological innovation and large-scale production.
Breaking Technological Barriers, Driving Industry Transformation
BiBo Pharma is the world’s first and only CDMO (Contract Development and Manufacturing Organization) to establish an ultra-large scale mammalian cell production line with a single-tank working volume of 30,000 liters. This groundbreaking achievement not only overcomes industry technical barriers but also provides a practical solution for significantly reducing the production costs of protein-based drugs. By doing so, BiBo Pharma has greatly enhanced the affordability and accessibility of biologic drugs, bringing hope to patients worldwide and fully demonstrating its commitment to advancing the biopharmaceutical industry.
At the awards ceremony, BiBo Pharma’s Senior VP, Qi Xu, stated that winning the “Emerging CDMO of the Year” award signifies recognition of BiBo Pharma as a rising force in the global biopharmaceutical sector. It also acknowledges the company’s decade-long efforts to improve the overall supply chain of biologics across Asia and the world. He emphasized that the BiBo team will continue to focus on technological innovation and enhance service capabilities, contributing to the affordability and accessibility of biologic drugs globally.
Looking Ahead: Continuous Innovation, Serving the World
BiBo Pharma’s success is not only reflected in its technological breakthroughs and industry recognition but also in its profound impact on the global biopharmaceutical industry. Moving forward, BiBo Pharma will remain committed to innovation, driving advancements in biopharmaceutical technology, and providing more accessible and affordable biologic drugs to patients worldwide, contributing to the advancement of global health.
Winning the Asia-Pacific Biopharma Excellence Award marks a significant milestone in BiBo Pharma’s journey and lays a solid foundation for its future global expansion.
